Kirkland & Ellis LLP advised Pamplona Capital Management LLP, a specialist investment manager, on its acquisition of PAREXEL International (NASDAQ:PRXL), a leading global biopharmaceutical provider, for approximately $5 billion. Upon completion of the transaction PAREXEL will become a privately held company and shares of its common stock will no longer be listed on any public market. The transaction is subject to approval by PAREXEL shareholders and other customary closing conditions. The transaction is expected to close in the fourth quarter of 2017. The full release is available here.
The Kirkland team was led by corporate partners Peter Martelli and Jonathan Davis and associates Dylan Hanson, Michelle Miao and Michael Marcantonio.